CONTEXT: Acylcarnitines are biomarkers of incomplete β-oxidation and mitochondrial lipid overload but indicate also high rates of mitochondrial fatty acid oxidation. It is unknown whether the production of acylcarnitines in primary human myotubes obtained from lean, metabolically healthy subjects reflects the fat oxidation in vivo. OBJECTIVE: Our objective was to quantify the acylcarnitine production in myotubes obtained from subjects with low and high fasting respiratory quotient (RQ). METHODS: Fasting RQ was determined by indirect calorimetry. Muscle biopsies from the vastus lateralis muscle were taken from 6 subjects with low fasting RQ (mean 0.79 ± 0.03) and 6 with high fasting RQ (0.90 ± 0.03), and satellite cells were isolated, cultured, and differentiated to myotubes. Myotubes were cultivated with 125 μM (13)C-labeled palmitate for 30 minutes and 4 and 24 hours. Quantitative profiling of 42 intracellular and 31 extracellular acylcarnitines was performed by stable isotope dilution-based metabolomics analysis by liquid chromatography coupled to mass spectrometry. RESULTS: Myotubes from donors with high fasting RQ produced and released significant higher amounts of medium-chain acylcarnitines. High (13)C8 and (13)C10 acylcarnitine levels in the extracellular compartment correlated with high fasting RQ. The decreased expression of medium-chain acyl-coenzyme A dehydrogenase (MCAD) in these myotubes can explain the higher rate of incomplete fatty acid oxidation. A lower intracellular [(13)C]acetylcarnitine to carnitine and lower intracellular (13)C16/(13)C18 acylcarnitine to carnitine ratio indicate reduced fatty acid oxidation capacity in these myotubes. Mitochondrial DNA content was not different. CONCLUSION: Acylcarnitine production and release from primary human myotubes of donors with high fasting RQ indicate a reduced fatty acid oxidation capacity and a higher rate of incomplete fatty acid oxidation. Thus, quantitative profiling of acylcarnitine production in human myotubes can be a suitable tool to identify muscular determinants of fat oxidation in vivo.
CONTEXT: Acylcarnitines are biomarkers of incomplete β-oxidation and mitochondrial lipid overload but indicate also high rates of mitochondrial fatty acid oxidation. It is unknown whether the production of acylcarnitines in primary human myotubes obtained from lean, metabolically healthy subjects reflects the fat oxidation in vivo. OBJECTIVE: Our objective was to quantify the acylcarnitine production in myotubes obtained from subjects with low and high fasting respiratory quotient (RQ). METHODS: Fasting RQ was determined by indirect calorimetry. Muscle biopsies from the vastus lateralis muscle were taken from 6 subjects with low fasting RQ (mean 0.79 ± 0.03) and 6 with high fasting RQ (0.90 ± 0.03), and satellite cells were isolated, cultured, and differentiated to myotubes. Myotubes were cultivated with 125 μM (13)C-labeled palmitate for 30 minutes and 4 and 24 hours. Quantitative profiling of 42 intracellular and 31 extracellular acylcarnitines was performed by stable isotope dilution-based metabolomics analysis by liquid chromatography coupled to mass spectrometry. RESULTS: Myotubes from donors with high fasting RQ produced and released significant higher amounts of medium-chain acylcarnitines. High (13)C8 and (13)C10 acylcarnitine levels in the extracellular compartment correlated with high fasting RQ. The decreased expression of medium-chain acyl-coenzyme A dehydrogenase (MCAD) in these myotubes can explain the higher rate of incomplete fatty acid oxidation. A lower intracellular [(13)C]acetylcarnitine to carnitine and lower intracellular (13)C16/(13)C18 acylcarnitine to carnitine ratio indicate reduced fatty acid oxidation capacity in these myotubes. Mitochondrial DNA content was not different. CONCLUSION:Acylcarnitine production and release from primary human myotubes of donors with high fasting RQ indicate a reduced fatty acid oxidation capacity and a higher rate of incomplete fatty acid oxidation. Thus, quantitative profiling of acylcarnitine production in human myotubes can be a suitable tool to identify muscular determinants of fat oxidation in vivo.
Authors: Jakob S Hansen; Xinjie Zhao; Martin Irmler; Xinyu Liu; Miriam Hoene; Mika Scheler; Yanjie Li; Johannes Beckers; Martin Hrabĕ de Angelis; Hans-Ulrich Häring; Bente K Pedersen; Rainer Lehmann; Guowang Xu; Peter Plomgaard; Cora Weigert Journal: Diabetologia Date: 2015-06-12 Impact factor: 10.122
Authors: Céline Aguer; Colin S McCoin; Trina A Knotts; A Brianne Thrush; Kikumi Ono-Moore; Ruth McPherson; Robert Dent; Daniel H Hwang; Sean H Adams; Mary-Ellen Harper Journal: FASEB J Date: 2014-10-23 Impact factor: 5.191
Authors: Anjali K Nath; Junyan Ma; Zsu-Zsu Chen; Zhuyun Li; Maria Del Carmen Vitery; Michelle L Kelley; Randall T Peterson; Robert E Gerszten; Jing-Ruey J Yeh Journal: FASEB J Date: 2019-12-02 Impact factor: 5.191
Authors: Manuel Mai; Anke Tönjes; Peter Kovacs; Michael Stumvoll; Georg Martin Fiedler; Alexander Benedikt Leichtle Journal: PLoS One Date: 2013-12-16 Impact factor: 3.240
Authors: Bodil Ingerslev; Jakob S Hansen; Christoph Hoffmann; Jens O Clemmesen; Niels H Secher; Mika Scheler; Martin Hrabĕ de Angelis; Hans U Häring; Bente K Pedersen; Cora Weigert; Peter Plomgaard Journal: Mol Metab Date: 2017-07-08 Impact factor: 7.422
Authors: Olivia McCarthy; Jason Pitt; Rachel Churm; Gareth J Dunseath; Charlotte Jones; Lia Bally; Christos T Nakas; Rachel Deere; Max L Eckstein; Stephen C Bain; Othmar Moser; Richard M Bracken Journal: BMJ Open Diabetes Res Care Date: 2020-10